Global Taurodontism Treatment Market, By Treatment (Surgery, Drugs, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Taurodontism Treatment Market Analysis and Size
The increase in the occurrences of taurodontism among the population is one of the major factors boosting the growth of taurodontism treatment market. The development of disease-modifying therapies as a substitute for the unmet medical needs of patients and huge developments in the treatment and therapies and novel treatment for rare diseases fastens the market growth. The increasing growth in awareness associated with the orphan drugs for “orphan diseases” and the increase in research and activities to improve the treatment facilities further influence the market growth.
Data Bridge Market Research analyses a growth rate in taurodontism treatment market in the forecast period 2023-2030. The expected CAGR of taurodontism treatment market is tend to be around 4.50% in the mentioned forecast period. The market was valued at USD 100 million in 2022, and it would grow upto USD 142.21 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Taurodontism Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023-2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Surgery, Drugs, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Bausch Health Companies Inc. (Canada), Regeneron Pharmaceuticals Inc (U.S.), Mallinckrodt (U.K.)., Swedish Orphan Biovitrum AB (Sweden)
|
|
Market Opportunities
|
|
Market Definition
Taurodontism is a change in tooth shape primarily resulted from the failure of Hertwig's epithelial sheath diaphragm in invaginating at the proper horizontal level. The condition consists of ty[ical characteristics such as no constriction at the level of the cemento-enamel junction, apical displacement of the pulpal floor, and an enlarged pulp chamber. Permanent molar teeth tend to be significantly affected by the tooth disorder.
Taurodontism Treatment Market Dynamics
Drivers
- Increasing Demands of Diagnostic Tests
There are numerous diagnostic tests that are boosting the demand of the market. There are precise biometric methods that are essential in diagnosis of taurodontism. It is a simple method of evaluating taurodontism using orthopantomograms by measuring the distance between the baseline and the highest point of the floor of the pulp chamber. Radiographic examination is also performed to confirm the diagnosis.
Opportunities
- Growing Demand of Different Treatment Methods
There are numerous treatment methods that are helping in boosting the growth of the market. Endodontic treatment, also known as root canal therapy, is used to treat several cases of taurodontism. In this process, a cavity is created to access the root, which is then destroyed and filled. After the root canal has been cleaned and filled, a dental crown is placed on the affected tooth. Thus, this boosts the market growth.
Restraints/Challenges
- Discontinuation of Drug Trials
The drug development for the disease has faced major obstacles as many therapies have failed to demonstrate efficacy or were associated with major toxicity. Thus, this impedes the growth of the market.
This taurodontism treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the taurodontism treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Taurodontism Treatment Market Scope
The taurodontism treatment market is segmented on the basis of types, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Types
- Surgery
- Drugs
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Taurodontism Treatment Market Regional Analysis/Insights
The taurodontism treatment market is analyzed and market size insights and trends are provided by types, , distribution channel and end-user as referenced above.
The major countries covered in the Taurodontism treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific will be expecting positive growth for taurodontism treatment market throughout the forecasted period due to increased research and development for producing effective drugs within the region.
North America dominates the market due to increased government awareness programs, advanced technology and treatment.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Taurodontism Treatment Market Share Analysis
The taurodontism treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to taurodontism treatment market.
Key players operating in the taurodontism treatment market include:
- Pfizer Inc (U.S.)
- Novartis AG (Switzerland)
- AbbVie Inc. (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- Abbott (U.S.)
- AbbVie Inc. (U.S.)
- Bausch Health Companies Inc. (Canada)
- Regeneron Pharmaceuticals Inc (U.S.)
- Mallinckrodt (U.K.)
- Swedish Orphan Biovitrum AB (Sweden)
SKU-